Table 1 Summary of anti-C1 mAb... | American Society of Hematology

Table 1

Summary of anti-C1 mAb characteristics

mAb no.	Name	Isotype	Group	Spleen prigin no.	BU/mg IgG	Inhibitor type	VWF binding IC₅₀ (µg/mL)	Phospholipid binding IC₅₀ (µg/mL)
1	2A9	IgG2aκ	A	1	23	II	1.1	0.9
2	B153	IgG2aκ	A	2	3	II	>10	>10
3	F156	IgG1κ	A	3	7	II	>10	>10
4	I41	IgG1κ	A	4	15	II	2.7	>10
5	I84	IgG2aκ	A	4	IND	II	3.3	>10
6	I88	IgG2aκ	A	4	3	II	1.7	>10
7	M6143	IgG1κ	A	5	180	II	0.6	>10
8	KM33	IgG1κ*	AB	†	3700	I	0.03	0.03
9	B136	IgG2aκ	B	2	700	I	0.4	0.04

mAb no.	Name	Isotype	Group	Spleen prigin no.	BU/mg IgG	Inhibitor type	VWF binding IC₅₀ (µg/mL)	Phospholipid binding IC₅₀ (µg/mL)
1	2A9	IgG2aκ	A	1	23	II	1.1	0.9
2	B153	IgG2aκ	A	2	3	II	>10	>10
3	F156	IgG1κ	A	3	7	II	>10	>10
4	I41	IgG1κ	A	4	15	II	2.7	>10
5	I84	IgG2aκ	A	4	IND	II	3.3	>10
6	I88	IgG2aκ	A	4	3	II	1.7	>10
7	M6143	IgG1κ	A	5	180	II	0.6	>10
8	KM33	IgG1κ*	AB	†	3700	I	0.03	0.03
9	B136	IgG2aκ	B	2	700	I	0.4	0.04

IND, indeterminate.

Human-derived mAb KM33 was donated as a full-length human IgG1K converted from the original scFv.

KM33 is a human-derived mAb.